Rocket Pharmaceuticals Secures Credit Facility from Hercules Capital

Rocket Pharmaceuticals secured a credit facility agreement for up to $150 million with Hercules Capital on October 6, 2026, according to financial disclosures. The commercial-stage biotechnology company announced that the capital will support its Phase 2 study of RP-A501 for Danon disease and the development of its cardiovascular genetic medicine pipeline.

Key Clinical Takeaways:
• Rocket Pharmaceuticals entered a $150 million credit facility with Hercules Capital on October 6, 2026, receiving $35 million at closing.
• The financing supports the Phase 2 clinical trial of gene therapy candidate RP-A501 targeting Danon disease.
• Combined with existing cash reserves of $283.7 million recorded in mid-2026, the initial funds extend operations into the third quarter of 2028.

Rocket Receives Initial Loan with Staged Draw Options

Under the terms of the agreement, Rocket received $35 million immediately at the closing date. The company holds the option to draw an additional $35 million during specified periods, subject to agreement conditions. An extra $30 million becomes available upon the achievement of a designated Danon clinical milestone, while a final $50 million tranche requires approval from Hercules Capital’s investment committee. The credit facility features an initial 30-month interest-only period coupled with a 48-month maturity, alongside extension options tied to milestone achievements and warrants for common stock purchase.

Cash Reserves Fund Operations into 2028

As of June 30, 2026, Rocket reported holdings of $283.7 million in cash, cash equivalents, and investments. Company leadership stated that these existing reserves, when paired with the initial $35 million loan draw, will fund operations into the third quarter of 2028. Additional borrowings under the facility could push the cash runway into 2029, depending on operating expenditures and the timing of future capital draws. LifeSci Capital acted as financial advisor for the term loan financing, while PJT served as capital markets advisor.

Financing Supports Gene Therapy for Cardiovascular Disorders

Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals, stated that the transaction diversifies the company’s capital sources following the sale of a priority review voucher. R. Bryan Jadot, Senior Managing Director and Group Head of Life Sciences at Hercules Capital, noted that the financing solution aligns with the company’s development priorities in inherited cardiovascular disorders. Rocket maintains three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies using adeno-associated virus manufacturing platforms.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.